Literature DB >> 7953603

Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside.

D A Kaku1, J D England, A J Sumner.   

Abstract

In four patients with a chronic, demyelinating polyneuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein (MAG) and sulphated glucuronyl paragloboside (SGPG), we have observed a marked prolongation of distal motor latencies disproportionate to proximal segment-conduction velocities, in nearly all nerves studied. Distal accentuation of conduction slowing distinguished these patients from those with Charcot-Marie-Tooth polyneuropathy type 1A, chronic inflammatory polyneuropathy, and from controls, as demonstrated by regression of distal motor latency on proximal conduction velocity. Sixteen of 21 nerves (76%) studied in the patients with anti-MAG/SGPG polyneuropathy had a terminal latency index of < or = 0.25 versus 11 of 195 nerves (6%) of Charcot-Marie-Tooth polyneuropathy type 1A patients, three of 49 nerves (6%) of patients with chronic inflammatory polyneuropathy and none of the controls (P = 0.0001). Recognition of this unique pattern of generalized, distally predominant conduction slowing in anti-MAG/SGPG polyneuropathy may be useful in clinically distinguishing this from other chronic demyelinating polyneuropathies, and in possibly providing insights into the pathophysiology of this disorder.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7953603     DOI: 10.1093/brain/117.5.941

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  29 in total

Review 1.  Immunological mechanisms in paraneoplastic peripheral neuropathy.

Authors:  J C Antoine
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 2.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

3.  Subclinical diabetic neuropathy with normal conventional electrophysiological study.

Authors:  Jong Seok Bae; Byoung Joon Kim
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

Review 4.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

5.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Authors:  Jean-Marc Léger; Karine Viala; Guillaume Nicolas; Alain Créange; Jean-Michel Vallat; Jean Pouget; Pierre Clavelou; Christophe Vial; Andreas Steck; Lucile Musset; Benoit Marin
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

Review 6.  Animal models of autoimmune neuropathy.

Authors:  Betty Soliven
Journal:  ILAR J       Date:  2014

Review 7.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

8.  Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins.

Authors:  G Lopate; B J Parks; J M Goldstein; W C Yee; G M Friesenhahn; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

Review 9.  Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases.

Authors:  E Ellie; A Vital; A Steck; J M Boiron; C Vital; J Julien
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

10.  Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG.

Authors:  A A Ilyas; Y Gu; M C Dalakas; R H Quarles; S Bhatt
Journal:  J Neuroimmunol       Date:  2007-11-26       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.